Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Multiple Sclerosis Health Center

Font Size

Don't Delay MS Treatment

Brain Creates New Lesions When Drug Therapy Delayed
WebMD Health News

Oct. 25, 2002 -- For people with multiple sclerosis (MS), a delay in treatment allows the disease to worsen.

A new study looks at treatment for relapsing-remitting MS, a form of the neurological disorder that involves acute attacks followed by recovery periods.

Those patients who didn't start drug therapy immediately -- who waited nine months after diagnosis -- accumulated new lesions in their brains, writes researcher Jerry S. Wolinsky, MD, director of the MS Research Group at the University of Texas Health Sciences Center in Houston.

His study appears in this month's edition of Neurology.

In his 18-month study, Wolinsky randomly assigned 224 MS patients to receive either the drug Copaxone or a placebo soon after diagnosis for the following nine months. Then all patients were given the active drug for the next nine months.

Teva Pharmaceuticals, the makers of Copaxone, supported this work.

"Over the entire 18 months of the study there were 35% fewer enhancing lesions among the patients who started drug therapy early," he says in a news release.

His study also finds that the group of patients receiving drug therapy continuously had 23% fewer relapses compared with the group who started active treatment nine months later. -->

Today on WebMD

nerve damage
Learn how this disease affects the nervous system.
woman applying lotion
Ideas on how to boost your mood and self-esteem.
woman pondering
Get personalized treatment options.
man with hand over eye
Be on the lookout for these symptoms.
brain scan
worried woman
neural fiber
white blood cells
sunlight in hands
marijuana plant
muscle spasm